Pharma Journalist

Impax declares the launch of generic version of Solodyn

By Sreoshi Chatterjee on February 21, 2018

Impax Laboratories asserted the roll out of generic version of Solodyn (minocycline HCl) extended-release tablets, 65 mg and 115 mg.

Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual U.S. sales of approximately $148 million according to IQVIA for the 12 months ending December 2017.

Related Posts

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO (Sulbactam-Durlobactam)

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates

Samsung Biologics signs manufacturing deal with European pharmaceutical company

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

European Commission Approves Pfizer’s HYMPAVZI (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
Comments (0)
Add Comment